Meiji Yasuda Asset Management Co Ltd. Takes Position in Edwards Lifesciences Corporation $EW

Meiji Yasuda Asset Management Co Ltd. bought a new stake in Edwards Lifesciences Corporation (NYSE:EW) in the second quarter, according to its most recent filing with the Securities & Exchange Commission. The firm bought 53,418 shares of the medical research company’s stock, valued at approximately $4,832,000.

Several other institutional investors and hedge funds have also recently bought and sold shares of EW. Brighton Jones LLC purchased a new stake in Edwards Lifesciences during the 4th quarter worth about $266,000. NewEdge Advisors LLC boosted its stake in shares of Edwards Lifesciences by 8.1% in the 2nd quarter. NewEdge Advisors LLC now owns 35,637 shares of the medical research company’s stock valued at $2,787,000 after buying an additional 2,665 shares during the period. Sei Investments Co. boosted its stake in shares of Edwards Lifesciences by 16.7% in the 2nd quarter. Sei Investments Co. now owns 412,808 shares of the medical research company’s stock valued at $32,285,000 after buying an additional 58,988 shares during the period. Squarepoint Ops LLC grew its position in shares of Edwards Lifesciences by 277.7% during the second quarter. Squarepoint Ops LLC now owns 69,263 shares of the medical research company’s stock worth $5,417,000 after buying an additional 50,924 shares in the last quarter. Finally, Treasurer of the State of North Carolina grew its position in shares of Edwards Lifesciences by 0.4% during the second quarter. Treasurer of the State of North Carolina now owns 268,860 shares of the medical research company’s stock worth $21,028,000 after buying an additional 1,065 shares in the last quarter. 79.46% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several analysts recently weighed in on the stock. Citigroup raised their target price on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the company a “buy” rating in a report on Wednesday, July 8th. Barclays reiterated an “overweight” rating and set a $110.00 price target (up from $104.00) on shares of Edwards Lifesciences in a report on Monday, April 27th. Wall Street Zen downgraded shares of Edwards Lifesciences from a “buy” rating to a “hold” rating in a research report on Saturday, July 4th. Leerink Partners upgraded shares of Edwards Lifesciences from a “market perform” rating to an “outperform” rating and raised their price objective for the company from $87.00 to $101.00 in a report on Friday, July 24th. Finally, Evercore reaffirmed an “outperform” rating and set a $100.00 price objective on shares of Edwards Lifesciences in a research report on Monday, July 6th. Seventeen equities research analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. Based on data from MarketBeat.com, Edwards Lifesciences presently has a consensus rating of “Moderate Buy” and a consensus price target of $100.27.

Insider Transactions at Edwards Lifesciences

In related news, VP Daniel J. Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president directly owned 40,034 shares of the company’s stock, valued at $3,684,329.02. This trade represents a 1.52% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Andrew M. Dahl sold 568 shares of Edwards Lifesciences stock in a transaction on Friday, May 29th. The stock was sold at an average price of $86.08, for a total transaction of $48,893.44. Following the sale, the senior vice president owned 15,334 shares in the company, valued at $1,319,950.72. This represents a 3.57% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 25,570 shares of company stock worth $2,219,390. 0.31% of the stock is currently owned by insiders.

Edwards Lifesciences Price Performance

Shares of NYSE EW opened at $89.89 on Monday. The company has a debt-to-equity ratio of 0.06, a quick ratio of 3.77 and a current ratio of 4.52. Edwards Lifesciences Corporation has a fifty-two week low of $72.30 and a fifty-two week high of $96.29. The firm has a market capitalization of $51.76 billion, a PE ratio of 51.66, a price-to-earnings-growth ratio of 2.25 and a beta of 0.85. The stock’s 50-day simple moving average is $89.21 and its 200-day simple moving average is $84.68.

Edwards Lifesciences (NYSE:EW) last posted its earnings results on Thursday, July 23rd. The medical research company reported $0.78 earnings per share for the quarter, topping the consensus estimate of $0.74 by $0.04. The firm had revenue of $1.74 billion during the quarter, compared to analysts’ expectations of $1.70 billion. Edwards Lifesciences had a return on equity of 15.68% and a net margin of 15.43%.The firm’s revenue was up 13.6% compared to the same quarter last year. During the same quarter in the previous year, the business earned $0.67 earnings per share. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts forecast that Edwards Lifesciences Corporation will post 3 EPS for the current fiscal year.

About Edwards Lifesciences

Edwards Lifesciences is a medical technology company focused on products and therapies for structural heart disease and critical care monitoring. The company designs, develops and manufactures prosthetic heart valves and related delivery systems used in both surgical and minimally invasive (transcatheter) procedures. Its portfolio addresses a range of valvular conditions, with an emphasis on technologies that enable transcatheter aortic valve replacement (TAVR) as an alternative to open-heart surgery.

In addition to transcatheter heart valves—including the widely recognized SAPIEN family—Edwards offers surgical tissue valves and ancillary devices used by cardiac surgeons, interventional cardiologists and hospital teams.